Protalix BioTherapeutics, Inc.

AMEX:PLX

Biotechnology

Healthcare
$3.02 +4.21%

+$0.09 today

Market cap
$254.64M
Beta
0.01
P/E (TTM)
11.0
EPS (TTM)
$0.19
52W Low $1.32High $3.19

Volume 0.96M

Average 0.81M

PLX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Protalix BioTherapeutics, Inc.AMEX: PLX

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 79.85M shares rose 4.2% year over year, behind the +6.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.7% from the prior quarter. Over 3 fiscal years it compounded at +17.5% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +4.2% toward the trailing-twelve-month pace of +6.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
79.85M+1.7% QoQ
Last fiscal yearDec 2025
78.55M+8.3% YoY
LTMMar 2026
79.09M+6.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.2%——
1 year+8.3%——
3-year CAGR+17.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
78.55M USD
Year-over-year change
+8.3%
4-year CAGR
+15.5%

Weighted Avg Shares vs competitors

How PLX compares with its peers on the latest reported figures

  • PLX's LTM Mar 2026 weighted avg shares of 79.09M shares is the 3rd highest of the 4 companies compared; the peer median is 99.68M shares.
  • Its year-over-year change of +6.5% is the 2nd highest of 3, against a peer median of +0.8%.
  • Over three fiscal years its annual growth of +17.5% compares with a peer median of +3.7%.
PLX Competitors Peer median
Weighted Avg Shares for PLX and competitors
Company Period LTM YoY 3-year CAGR
PLYXPolaryx Therapeutics, Inc. Common StockLTM Mar 2026118.33M ——
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202699.68M +6.6%+12.1%
PLXProtalix BioTherapeutics, Inc.LTM Mar 202679.09M +6.5%+17.5%
PHARPharming Group N.V.LTM Mar 202667.56M -5.0%-4.8%
Peer median (excluding PLX) 99.68M+0.8%+3.7%

Competitors are the stored peer set for PLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue38.35M47.64M65.49M53.4M52.74M
Cost of Revenue16.35M19.59M22.98M24.32M27.51M
Gross Profit22M28.05M42.51M29.08M25.24M
Gross Margin57.4%58.9%64.9%54.5%47.8%
Research & Development29.73M29.35M17.09M12.97M19.05M
Selling, General & Admin12.73M11.71M14.96M12.19M11.68M
Operating Expenses42.46M41.06M32.05M25.16M30.74M
Depreciation & Amortization1.12M1.09M1.19M1.3M1.47M
EBITDA(18.94M)(10.78M)12.94M6.52M(2.95M)
EBITDA Margin-49.4%-22.6%19.8%12.2%-5.6%
Operating Income(20.46M)(13.01M)10.46M3.92M(5.5M)
Operating Margin-53.4%-27.3%16.0%7.3%-10.4%
Interest Income401K1.15M1.29M1.3M1.08M
Interest Expense7.52M2.53M3.18M1.06M1.19M
Other Income / Expenses(7.12M)(1.38M)(1.89M)237K(108K)
Income Before Tax(27.58M)(14.4M)8.57M4.15M(5.61M)
Pre-Tax Margin-71.9%-30.2%13.1%7.8%-10.6%
Income Tax Expense0530K254K1.22M996K
Net Income(27.58M)(14.93M)8.31M2.93M(6.6M)
Net Margin-71.9%-31.3%12.7%5.5%-12.5%
EPS (Basic)(0.62)(0.31)0.120.04(0.08)
EPS (Diluted)(0.62)(0.31)0.100.04(0.08)
Weighted Avg Shares44.14M48.47M67.51M72.53M78.55M
Weighted Avg Shares (Diluted)44.14M48.47M82.42M81.06M78.55M

Protalix BioTherapeutics, Inc.

AMEX:PLX

Intrinsic Alpha fair value

Locked

Current Price

$3.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.